First-Line ARBs for Hypertension
ARBs are recommended as first-line monotherapy for hypertension at Grade B evidence level, with all available ARBs (losartan, valsartan, irbesartan, telmisartan, candesartan, olmesartan, azilsartan) considered acceptable initial choices. 1, 2, 3
Recommended ARBs and Initial Dosing
While guidelines do not specify which individual ARB to use, the evidence suggests:
Most Effective Options Based on Comparative Data:
Olmesartan: Demonstrated highest efficacy in reducing office BP (systolic and diastolic) with best safety profile 4
- Initial dose: 20 mg once daily
- Maximum: 40 mg once daily
Telmisartan: Best for 24-hour ambulatory diastolic BP control with favorable adverse event profile 4
- Initial dose: 40 mg once daily
- Maximum: 80 mg once daily
Candesartan: Highest ranking for 24-hour ambulatory systolic BP reduction 4
- Initial dose: 8-16 mg once daily
- Maximum: 32 mg once daily
Other Acceptable First-Line ARBs:
- Losartan: 50 mg once daily (maximum 100 mg)
- Valsartan: 80-160 mg once daily (maximum 320 mg)
- Irbesartan: 150 mg once daily (maximum 300 mg)
- Azilsartan: 40 mg once daily (maximum 80 mg)
Clinical Context for ARB Selection
When ARBs are particularly indicated:
- Patients <60 years with uncomplicated hypertension 1
- Patients with diabetes and albuminuria (ACR >2.0 mg/mmol in men or >2.8 mg/mmol in women) 5
- Patients with left ventricular hypertrophy 5
- ACE inhibitor-intolerant patients (due to cough) 6, 7
- Patients requiring metabolically neutral antihypertensive therapy 6
When ARBs should NOT be first-line:
- Black patients with uncomplicated hypertension (ACE inhibitors also not recommended; prefer thiazide diuretics or CCBs) 1
- Patients ≥60 years with isolated systolic hypertension (thiazide diuretics or long-acting dihydropyridine CCBs preferred as Grade A) 1
Combination Therapy Considerations
If monotherapy insufficient, preferred combinations include:
Critical caveat: Never combine ARB with ACE inhibitor (Grade A recommendation against) 1, 8, 1, 3
Practical Dosing Strategy
Initial approach:
- Start at least half the maximum recommended dose to minimize need for multiple titrations 9
- Reassess BP every 2-4 weeks until controlled 9
- If BP remains ≥20/10 mmHg above target after 3-6 months, add second agent rather than maximizing monotherapy 1
For patients with BP ≥20/10 mmHg above target: Consider initiating combination therapy immediately (Grade C), but exercise caution in elderly or frail patients 1
Important Clinical Nuances
The most recent comparative evidence 4 suggests olmesartan and telmisartan offer the best balance of efficacy and tolerability, though older ARBs (losartan, valsartan) remain acceptable alternatives. ARBs demonstrate superior tolerability compared to ACE inhibitors 6, 10, making them preferable when cough or angioedema risk is a concern.
Common pitfall: Prescribing ARBs to black patients as first-line for uncomplicated hypertension—this population responds better to thiazide diuretics or CCBs 1.